Neurosense Therapeutics LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
NeuroSense Therapeutics Ltd. reported positive long-term survival data for its lead ALS drug candidate, PrimeC, from its Phase 2b PARADIGM study, while also highlighting a substantial doubt about its ability to continue as a going concern without additional financing.
NASDAQ
NeuroSense Therapeutics reports its 2024 financial results, highlighting its focus on developing treatments for neurodegenerative diseases and providing an update on its clinical programs.
NASDAQ
NeuroSense Therapeutics' 20-F filing highlights clinical trial progress, financial status, and key risk factors for investors.